Zepbound for PCOS: Off-Label Use, Evidence Summary, and What to Expect

Is Zepbound approved for PCOS?

No. The Zepbound label lists two indications, both used with a reduced-calorie diet and more physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition; and to treat moderate-to-severe obstructive sleep apnea in adults with obesity [1]. Polycystic ovary syndrome is not one of them, so any use in PCOS is off-label.

Some background on PCOS helps explain the interest in weight-loss drugs. The CDC describes PCOS as a common cause of infertility, affecting as many as 5 million women, notes that women with PCOS often have insulin resistance, and states that more than half of women with PCOS develop type 2 diabetes by age 40 [5]. The Endocrine Society's 2013 clinical practice guideline recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism or acne, clomiphene as first-line for infertility, and metformin for metabolic and glycemic abnormalities and menstrual irregularity, with limited or no benefit from metformin for hirsutism, acne, or infertility [6]. That guideline also states that the role of weight loss in improving PCOS status per se is uncertain, while lifestyle intervention is beneficial in overweight and obese patients for other health reasons [6].

What the PCOS trial of tirzepatide showed

The trial randomized 60 overweight or obese Chinese women with PCOS to metformin 1,000 mg twice daily or metformin plus tirzepatide 5 mg once weekly for 16 weeks [2]. Weight fell 10.4 plus or minus 3.5 kg with the combination versus 1.7 plus or minus 2.5 kg with metformin alone (p < 0.001), BMI fell 4.12 versus 0.68 kg/m², and visceral adipose tissue fell 34.13 versus 4.67 cm² [2]. Menstrual cycle recovery and total pregnancy rate were both higher in the combination group (p = 0.013 and p = 0.014) [2].

After week 16 everyone switched to metformin alone; barrier contraception was required for 8 weeks and pregnancy outcomes were evaluated between weeks 25 and 48 [2].

The limits are as important as the results. It was open-label, lasted 16 weeks, used a single 5 mg dose, and every participant also took metformin, so it says nothing about tirzepatide as monotherapy or about the 10 mg and 15 mg maintenance doses the label recommends for weight management [1][2].

What other GLP-1 drugs have shown in PCOS

Most PCOS data in this drug class come from older agents, chiefly liraglutide. A 2020 review found that GLP-1 receptor agonists, mainly liraglutide, given alone or with metformin, produced significant weight loss and testosterone reduction in women with obesity and PCOS, with mixed results for insulin resistance parameters and menstrual patterns; it also states that weight reduction is the most significant factor affecting fertility and pregnancy outcomes [7]. A 2026 review of 47 articles reports increased menstrual regularity, ovulation and pregnancy rates, particularly with metformin, and cites one randomized trial in which pregnancy rates were 69.2% with liraglutide plus metformin versus 35.4% with metformin alone (p < 0.05) [8]. A 2025 gynecology review notes that GLP-1 receptor agonists may improve weight, metabolic dysfunction and menstrual regularity in PCOS, and that recent studies showed higher spontaneous conception and pregnancy rates with combined GLP-1 plus metformin therapy before IVF, while calling for further study [9].

A 2026 evidence-map review of liraglutide, semaglutide and tirzepatide concluded that liraglutide has the densest PCOS-specific data and semaglutide data remain sparse, and it described a gap in PCOS-specific tirzepatide evidence [3]. The 60-woman randomized trial above is PCOS-specific evidence for tirzepatide plus metformin [2].

How much weight loss does tirzepatide produce?

In SURMOUNT-1, 2,539 adults with obesity, or overweight plus a weight-related complication and no diabetes, received 5, 10 or 15 mg or placebo for 72 weeks; mean weight change was -15.0%, -19.5% and -20.9% versus -3.1% with placebo [4]. In SURMOUNT-2, 938 adults with overweight or obesity (BMI 27 or higher) and type 2 diabetes lost 12.8% (10 mg) and 14.7% (15 mg) versus 3.2% with placebo, per the label [10]. In a head-to-head trial of 751 adults with obesity and no diabetes, tirzepatide produced -20.2% versus -13.7% with semaglutide at 72 weeks [11].

A body-composition substudy of 160 SURMOUNT-1 participants found changes of -21.3% body weight, -33.9% fat mass and -10.9% lean mass with tirzepatide versus -5.3%, -8.2% and -2.6% with placebo; about 75% of the weight lost was fat mass and 25% lean mass in both groups [12]. In SURMOUNT-4, weight changed -5.5% from week 36 to week 88 in people who continued tirzepatide versus +14.0% in those switched to placebo [13].

None of these trials enrolled women selected for PCOS, so the numbers describe what the drug does in obesity generally, not what it does to menstrual cycles or androgen levels.

Dosing, per the label

The Zepbound label starts everyone at 2.5 mg subcutaneously once weekly for 4 weeks, a dose it describes as initiation only and not approved for maintenance, then moves to 5 mg, with further 2.5 mg increases after at least 4 weeks on the current dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg weekly; the maximum is 15 mg weekly, and the label advises considering a lower maintenance dose if a dose is not tolerated [1]. The label says a missed dose should be given as soon as possible within 4 days, and that a dose missed by more than 4 days is skipped; the weekly day can be changed if doses are at least 3 days apart [1]. It allows dosing at any time of day, with or without food, into the abdomen, thigh or back of the upper arm, with rotation of sites [1]. The label states no dose adjustment is needed for renal or hepatic impairment [1].

Side effects and label warnings

In the pooled Zepbound weight-management trials (958 placebo, 630 at 5 mg, 948 at 10 mg, 941 at 15 mg), the label reports nausea in 25%, 29% and 28% versus 8% with placebo; diarrhea in 19%, 21% and 23% versus 8%; vomiting in 8%, 11% and 13% versus 2%; and constipation in 17%, 14% and 11% versus 5% [1]. Any gastrointestinal adverse reaction occurred in 56% on every tirzepatide dose versus 30% with placebo, and most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. Severe gastrointestinal reactions occurred in 1.7% (5 mg), 2.5% (10 mg) and 3.1% (15 mg) versus 1% with placebo, and the label states Zepbound is not recommended in patients with severe gastroparesis [1].

Hair loss is listed in the label at 5%, 4% and 5% versus 1% with placebo; the label states it was associated with weight reduction and was more frequent in women (7.1% of women versus 0.5% of men on Zepbound), and no Zepbound-treated patient discontinued treatment for it [1].

Gallbladder events in the same pool were cholelithiasis 1.1% versus 1%, cholecystitis 0.7% versus 0.2%, and cholecystectomy 0.2% versus none [1]. Acute pancreatitis has been observed, and the label says to discontinue Zepbound if pancreatitis is suspected [1]. The boxed warning covers thyroid C-cell tumors in rats, with human relevance unknown, and Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. On pregnancy, the label states that weight loss offers no benefit during pregnancy and may cause fetal harm, and that Zepbound should be discontinued when pregnancy is recognized [1].

Birth control, ovulation and pregnancy

The label states that Zepbound may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying, that this delay is largest after the first dose and diminishes over time, and that patients using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation; hormonal methods that are not oral should not be affected [1]. In a pharmacokinetic study of a single 5 mg dose given with a pill containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate, peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell 59%, 66% and 55%, while total exposure fell 20%, 21% and 23% [1].

The Endocrine Society guideline lists hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism or acne in PCOS [6], so this label advice applies to a common PCOS treatment.

Two 2026 reviews describe a washout before conception, 8 to 10 weeks in one and 8 weeks in the other, citing limited human pregnancy data [8][14]; the label says to discontinue Zepbound when pregnancy is recognized [1]. In the PCOS trial, barrier contraception was required for 8 weeks, and the total pregnancy rate was higher in the tirzepatide-plus-metformin group [2].

Compounded tirzepatide

Compounded tirzepatide is not FDA approved and is not reviewed for safety, effectiveness or quality before marketing [15].

What to expect, and what is still unknown

In one 16-week randomized trial of 60 overweight or obese women with PCOS, tirzepatide 5 mg weekly added to metformin was associated with greater average weight loss, visceral-fat reduction, menstrual-cycle recovery and pregnancy rates than metformin alone [2]. It does not answer whether tirzepatide works on its own in PCOS, whether 10 or 15 mg adds benefit, what happens to hirsutism or acne, or how androgens behave over a year or more. The 2026 evidence map lists reproductive outcomes, periconceptional and pregnancy safety, adolescent use, long-term cardiovascular-kidney-metabolic outcomes, sleep apnea, musculoskeletal health and phenotype-specific response as open questions for incretin therapy in PCOS [3]. A PCOS review states that therapeutic decisions depend on the patient's phenotype, concerns and goals, and should focus on suppressing androgen secretion and action, improving metabolic status, and improving fertility [16].